8-K Announcements
6Material company update
Apr 21, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 27, 2026·SEC
Envoy Medical, Inc.(COCH)Earnings, Financials & Key Ratios
COCH•NASDAQ
$0.66
$14M mkt cap·Price updated May 7, 2026
AboutEnvoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices; and Acclaim cochlear implants. Envoy Medical Corporation was formerly known as St. Croix Medical, Inc. and changed its name to Envoy Medical Corporation in December 2004. The company was founded in 1995 and is based in White Bear Lake, Minnesota.Show more
- Revenue$241K+7.1%
- EBITDA-$22M-15.1%
- Net Income-$24M-14.2%
- EPS (Diluted)-1.23+17.4%
- Gross Margin-262.66%-14.3%
- EBITDA Margin-9115.35%-7.5%
- Operating Margin-9240.66%-8.0%
- Net Margin-9857.26%-6.7%
- Interest Coverage-14.01+42.8%
COCH Key Insights
Envoy Medical, Inc. (COCH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
COCH Price & Volume
Envoy Medical, Inc. (COCH) stock price & volume — 10-year historical chart
Loading chart...
COCH Growth Metrics
Envoy Medical, Inc. (COCH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years0.56%
TTM7.11%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-14.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM12.77%
Return on Capital
10 Years-2150.23%
5 Years-2150.23%
3 Years-2944.51%
Last Year-4471.89%
COCH Peer Comparison
Envoy Medical, Inc. (COCH) competitors in Vision, dental, and ENT devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LNTH | 5.92B | 91.00 | 26.69 | 0.5% | 18.05% | 24.33% | 0.00 | |
 MDT | 99.94B | 77.96 | 21.60 | 3.62% | 13% | 9.45% | 0.59 | |
 ABT | 151.3B | 87.01 | 11.39 | 4.59% | 31.88% | 27.26% | 0.32 | |
 BSX | 84.08B | 56.58 | 29.16 | 19.87% | 14.4% | 12.4% | 0.51 | |
 WST | 23.2B | 321.85 | 47.33 | 6.26% | 16.85% | 17.87% | 0.13 | |
 ITGR | 3.03B | 87.92 | 30.42 | 7.57% | 7.67% | 8.23% | 0.80 | |
 AEIS | 13.38B | 351.94 | 91.65 | 21.37% | 10% | 14.35% | 0.50 | |
 NOVT | 4.86B | 136.28 | 92.71 | 3.3% | 5.49% | 4.1% | 0.26 |
Compare COCH vs Peers
Envoy Medical, Inc. (COCH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
COCH Income Statement
Envoy Medical, Inc. (COCH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Sales/Revenue | 310K | 237K | 316K | 225K | 241K |
| Revenue Growth % | - | -23.55% | 33.33% | -28.8% | 7.11% |
| Cost of Goods Sold | 769K | 498K | 789K | 742K | 874K |
| COGS % of Revenue | 248.06% | 210.13% | 249.68% | 329.78% | 362.66% |
| Gross Profit | -459K▲ 0% | -261K▲ 43.1% | -473K▼ 81.2% | -517K▼ 9.3% | -633K▼ 22.4% |
| Gross Margin % | -148.06% | -110.13% | -149.68% | -229.78% | -262.66% |
| Gross Profit Growth % | - | 43.14% | -81.23% | -9.3% | -22.44% |
| Operating Expenses | 6.41M | 8.45M | 17.89M | 18.74M | 21.64M |
| OpEx % of Revenue | 2068.39% | 3563.29% | 5660.13% | 8328.44% | 8978.01% |
| Selling, General & Admin | 2.47M | 3.47M | 8.93M | 8.56M | 9.15M |
| SG&A % of Revenue | 797.74% | 1464.13% | 2825.95% | 3804.44% | 3797.1% |
| Research & Development | 3.94M | 4.97M | 8.96M | 10.18M | 12.49M |
| R&D % of Revenue | 1270.65% | 2099.16% | 2834.18% | 4524% | 5180.91% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -6.87M▲ 0% | -8.71M▼ 26.7% | -18.36M▼ 110.9% | -19.26M▼ 4.9% | -22.27M▼ 15.7% |
| Operating Margin % | -2216.45% | -3673.42% | -5809.81% | -8558.22% | -9240.66% |
| Operating Income Growth % | - | -26.71% | -110.88% | -4.89% | -15.65% |
| EBITDA | -6.8M | -8.63M | -18.23M | -19.08M | -21.97M |
| EBITDA Margin % | -2193.55% | -3641.77% | -5767.72% | -8481.33% | -9115.35% |
| EBITDA Growth % | - | -26.93% | -111.17% | -4.7% | -15.12% |
| D&A (Non-Cash Add-back) | 71K | 75K | 133K | 173K | 302K |
| EBIT | -6.87M | -8.71M | -29.92M | -19.98M | -22.27M |
| Net Interest Income | 37.66K | 0 | 0 | -816K | -1.59M |
| Interest Income | 37.66K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 816K | 1.59M |
| Other Income/Expense | -1.8M | -7.22M | -11.56M | -1.54M | -1.49M |
| Pretax Income | -8.68M▲ 0% | -15.92M▼ 83.6% | -29.92M▼ 87.9% | -20.8M▲ 30.5% | -23.76M▼ 14.2% |
| Pretax Margin % | -2798.39% | -6718.57% | -9468.99% | -9242.22% | -9857.26% |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -8.68M▲ 0% | -15.92M▼ 83.6% | -29.92M▼ 87.9% | -20.8M▲ 30.5% | -23.76M▼ 14.2% |
| Net Margin % | -2798.39% | -6718.57% | -9468.99% | -9242.22% | -9857.26% |
| Net Income Growth % | - | -83.55% | -87.92% | 30.5% | -14.24% |
| Net Income (Continuing) | -8.68M | -15.92M | -29.92M | -20.8M | -23.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.05▲ 0% | -1.57▼ 49.5% | -2.54▼ 61.8% | -1.49▲ 41.3% | -1.23▲ 17.4% |
| EPS Growth % | - | -49.52% | -61.78% | 41.34% | 17.45% |
| EPS (Basic) | -1.05 | -1.57 | -2.54 | -1.49 | -1.23 |
| Diluted Shares Outstanding | 10.15M | 10.15M | 12.55M | 18.79M | 19.6M |
| Basic Shares Outstanding | 10.15M | 10.15M | 12.55M | 18.79M | 19.6M |
| Dividend Payout Ratio | - | - | - | - | - |
COCH Balance Sheet
Envoy Medical, Inc. (COCH) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Total Current Assets | 2.44M | 1.65M | 7.46M | 9.38M | 6.28M |
| Cash & Short-Term Investments | 1.12M | 183K | 4.22M | 5.48M | 3.74M |
| Cash Only | 1.12M | 183K | 4.22M | 5.48M | 3.74M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 88K | 41K | 70K | 818K | 34K |
| Days Sales Outstanding | 103.61 | 63.14 | 80.85 | 1.33K | 51.49 |
| Inventory | 1.06M | 1.29M | 1.4M | 1.71M | 1.55M |
| Days Inventory Outstanding | 503.12 | 949.15 | 649.51 | 840.19 | 645.64 |
| Other Current Assets | 0 | 0 | 176K | 1.38M | 960K |
| Total Non-Current Assets | 188K | 908K | 815K | 2.15M | 2.28M |
| Property, Plant & Equipment | 188K | 908K | 815K | 2.15M | 1.92M |
| Fixed Asset Turnover | 1.65x | 0.26x | 0.39x | 0.10x | 0.13x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 358K |
| Total Assets | 2.62M▲ 0% | 2.56M▼ 2.6% | 8.27M▲ 223.6% | 11.54M▲ 39.5% | 8.56M▼ 25.8% |
| Asset Turnover | 0.12x | 0.09x | 0.04x | 0.02x | 0.03x |
| Asset Growth % | - | -2.59% | 223.59% | 39.5% | -25.83% |
| Total Current Liabilities | 1.38M | 2.52M | 7.29M | 7.54M | 11.56M |
| Accounts Payable | 661K | 1M | 1.55M | 1.65M | 2.92M |
| Days Payables Outstanding | 313.74 | 735.13 | 718.9 | 812.64 | 1.22K |
| Short-Term Debt | 0 | 448K | 0 | 0 | 174K |
| Deferred Revenue (Current) | 15K | 15K | 0 | 0 | 0 |
| Other Current Liabilities | 379K | 320K | 1.76M | 5.74M | 4.69M |
| Current Ratio | 1.76x | 0.65x | 1.02x | 1.24x | 0.54x |
| Quick Ratio | 0.99x | 0.14x | 0.83x | 1.02x | 0.41x |
| Cash Conversion Cycle | 293 | 277.16 | 11.46 | 1.35K | -522.32 |
| Total Non-Current Liabilities | 46.2M | 36.23M | 2.76M | 22.84M | 8.76M |
| Long-Term Debt | 23.48M | 33.4M | 0 | 18.72M | 745K |
| Capital Lease Obligations | 0 | 565K | 404K | 802K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 22.72M | 2.27M | 2.36M | 3.32M | 8.02M |
| Total Liabilities | 47.58M | 38.75M | 10.05M | 30.38M | 20.32M |
| Total Debt | 23.48M | 34.53M | 562K | 19.66M | 919K |
| Net Debt | 22.36M | 34.35M | -3.66M | 14.18M | -2.82M |
| Debt / Equity | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | - | - | -24.48x | -14.01x |
| Total Equity | -44.96M▲ 0% | -36.2M▲ 19.5% | -1.78M▲ 95.1% | -18.84M▼ 960.9% | -11.77M▲ 37.5% |
| Equity Growth % | - | 19.5% | 95.09% | -960.92% | 37.55% |
| Book Value per Share | -4.43 | -3.56 | -0.14 | -1.00 | -0.60 |
| Total Shareholders' Equity | -44.96M | -36.2M | -1.78M | -18.84M | -11.77M |
| Common Stock | 1.39M | 1K | 2K | 2K | 3K |
| Retained Earnings | -210.06M | -225.99M | -257.26M | -284.73M | -313.4M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -108K | -115K | -118K | -123K | -120K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
COCH Cash Flow Statement
Envoy Medical, Inc. (COCH) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Cash from Operations | -6.94M | -8.8M | -17.09M | -17.95M | -18.2M |
| Operating CF Margin % | -2237.42% | -3715.19% | -5408.54% | -7977.33% | -7552.28% |
| Operating CF Growth % | - | -26.95% | -94.11% | -5.02% | -1.4% |
| Net Income | -8.68M | -15.92M | -29.92M | -22.45M | -23.76M |
| Depreciation & Amortization | 71K | 75K | 133K | 173K | 302K |
| Stock-Based Compensation | 0 | 0 | 1.57M | 0 | 88K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.75M | 7.2M | 12.11M | 4.97M | 3.33M |
| Working Capital Changes | -82K | -160K | -983K | -638K | 1.84M |
| Change in Receivables | -19K | 47K | -205K | -572K | 765K |
| Change in Inventory | 55K | -194K | -10K | -380K | 126K |
| Change in Payables | 227K | 342K | 551K | -19K | 1.39M |
| Cash from Investing | -125K | -218K | -153K | -980K | -179K |
| Capital Expenditures | -125K | -218K | -153K | -980K | -179K |
| CapEx % of Revenue | 40.32% | 91.98% | 48.42% | 435.56% | 74.27% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 8.06M | 8.09M | 21.28M | 20.2M | 16.63M |
| Debt Issued (Net) | 8M | 8M | 9.44M | 19.08M | 9.07M |
| Equity Issued (Net) | 0 | 92K | 11.85M | 3.56M | 9.44M |
| Dividends Paid | 0 | 0 | 0 | -2.45M | -1.82M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 58K | 0 | 0 | 0 | -62K |
| Net Change in Cash | 987K▲ 0% | 33.16K▼ 96.6% | 4.04M▲ 12070.1% | 1.26M▼ 68.6% | -1.74M▼ 237.9% |
| Free Cash Flow | -7.06M▲ 0% | -9.02M▼ 27.8% | -17.24M▼ 91.1% | -18.93M▼ 9.8% | -18.38M▲ 2.9% |
| FCF Margin % | -2277.74% | -3807.17% | -5456.96% | -8412.89% | -7626.56% |
| FCF Growth % | - | -27.79% | -91.11% | -9.77% | 2.9% |
| FCF per Share | -0.70 | -0.89 | -1.37 | -1.01 | -0.94 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.55x | 0.57x | 0.86x | 0.77x |
| Interest Paid | 0 | 0 | 26K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
COCH Key Ratios
Envoy Medical, Inc. (COCH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross Margin | -148.06% | -110.13% | -149.68% | -229.78% | -262.66% |
| Net Margin | -2798.39% | -6718.57% | -9468.99% | -9242.22% | -9857.26% |
| Interest Coverage | - | - | - | -24.48x | -14.01x |
| FCF Conversion | 0.80x | 0.55x | 0.57x | 0.86x | 0.77x |
| Revenue Growth | - | -23.55% | 33.33% | -28.8% | 7.11% |
COCH SEC Filings & Documents
Envoy Medical, Inc. (COCH) SEC filings — annual & quarterly reports (10-K, 10-Q)
COCH Frequently Asked Questions
Envoy Medical, Inc. (COCH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Envoy Medical, Inc. (COCH) reported $0.2M in revenue for fiscal year 2025. This represents a 22% decrease from $0.3M in 2021.
Envoy Medical, Inc. (COCH) grew revenue by 7.1% over the past year. This is steady growth.
Envoy Medical, Inc. (COCH) reported a net loss of $23.8M for fiscal year 2025.
Dividend & Returns
Yes, Envoy Medical, Inc. (COCH) pays a dividend with a yield of 14.06%. This makes it attractive for income-focused investors.
Envoy Medical, Inc. (COCH) had negative free cash flow of $18.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More COCH
Envoy Medical, Inc. (COCH) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates